Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers
Lindsey N Aubuchon, Deanna H. Wong, Natasha Ramakrishnan, Samantha F. Greenberg, Rohan Reddy, Elena Lomonosova, Amanda J. Compadre, Kathleen E. Jackson, Danielle Kemper, Vrutti V. Mehta, Kellen Zoberi, Dineo Khabele, Elizabeth L. Christie, Mary Margaret Mullen, Priyanka Verma
This study shows that targeting ALC1 can enhance PARP inhibitor effectiveness in ovarian cancers, particularly in HRD and CCNE1-amplified tumors, with minimal toxicity.
bioRxiv · Mar 4, 2026 · PreprintCancer Biology